The use of granulocyte-macrophage colony-stimulating factor in bone marrow transplantation

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

GM-CSF represents an important advance in bone marrow transplantation. The drug can be given safely and does not appear to increase the risk of graft- versus-host disease or tumor relapse. This is a rare example of a new technology reducing the cost of health care. By shortening the duration of hospitalization, GM-CSF can significantly reduce the cost of a bone marrow transplant (Table 2). However, there are few data to support the conclusion that the reduction in the duration of neutropenia is associated with a superior survival. This attests to the excellent supportive care that has been developed for patients undergoing bone marrow transplantation. At present, GM-CSF has become a standard therapy in autologous bone marrow transplantation. However, the future will undoubtedly see the development of combinations of hematopoietic growth factors and/or new growth factors that will further improve our ability to perform bone marrow transplantation.

Original languageEnglish (US)
Pages (from-to)14-18
Number of pages5
JournalSeminars in hematology
Volume29
Issue number4 SUPPL. 3
StatePublished - Jan 1 1992

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Bone Marrow Transplantation
Intercellular Signaling Peptides and Proteins
Autologous Transplantation
Graft vs Host Disease
Neutropenia
Health Care Costs
Hospitalization
Bone Marrow
Technology
Transplants
Costs and Cost Analysis
Recurrence
Survival
Pharmaceutical Preparations
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

The use of granulocyte-macrophage colony-stimulating factor in bone marrow transplantation. / Armitage, James Olen.

In: Seminars in hematology, Vol. 29, No. 4 SUPPL. 3, 01.01.1992, p. 14-18.

Research output: Contribution to journalReview article

@article{3c919c2429854a97841e0b64de9a69c1,
title = "The use of granulocyte-macrophage colony-stimulating factor in bone marrow transplantation",
abstract = "GM-CSF represents an important advance in bone marrow transplantation. The drug can be given safely and does not appear to increase the risk of graft- versus-host disease or tumor relapse. This is a rare example of a new technology reducing the cost of health care. By shortening the duration of hospitalization, GM-CSF can significantly reduce the cost of a bone marrow transplant (Table 2). However, there are few data to support the conclusion that the reduction in the duration of neutropenia is associated with a superior survival. This attests to the excellent supportive care that has been developed for patients undergoing bone marrow transplantation. At present, GM-CSF has become a standard therapy in autologous bone marrow transplantation. However, the future will undoubtedly see the development of combinations of hematopoietic growth factors and/or new growth factors that will further improve our ability to perform bone marrow transplantation.",
author = "Armitage, {James Olen}",
year = "1992",
month = "1",
day = "1",
language = "English (US)",
volume = "29",
pages = "14--18",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 3",

}

TY - JOUR

T1 - The use of granulocyte-macrophage colony-stimulating factor in bone marrow transplantation

AU - Armitage, James Olen

PY - 1992/1/1

Y1 - 1992/1/1

N2 - GM-CSF represents an important advance in bone marrow transplantation. The drug can be given safely and does not appear to increase the risk of graft- versus-host disease or tumor relapse. This is a rare example of a new technology reducing the cost of health care. By shortening the duration of hospitalization, GM-CSF can significantly reduce the cost of a bone marrow transplant (Table 2). However, there are few data to support the conclusion that the reduction in the duration of neutropenia is associated with a superior survival. This attests to the excellent supportive care that has been developed for patients undergoing bone marrow transplantation. At present, GM-CSF has become a standard therapy in autologous bone marrow transplantation. However, the future will undoubtedly see the development of combinations of hematopoietic growth factors and/or new growth factors that will further improve our ability to perform bone marrow transplantation.

AB - GM-CSF represents an important advance in bone marrow transplantation. The drug can be given safely and does not appear to increase the risk of graft- versus-host disease or tumor relapse. This is a rare example of a new technology reducing the cost of health care. By shortening the duration of hospitalization, GM-CSF can significantly reduce the cost of a bone marrow transplant (Table 2). However, there are few data to support the conclusion that the reduction in the duration of neutropenia is associated with a superior survival. This attests to the excellent supportive care that has been developed for patients undergoing bone marrow transplantation. At present, GM-CSF has become a standard therapy in autologous bone marrow transplantation. However, the future will undoubtedly see the development of combinations of hematopoietic growth factors and/or new growth factors that will further improve our ability to perform bone marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0026470074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026470074&partnerID=8YFLogxK

M3 - Review article

C2 - 1362821

AN - SCOPUS:0026470074

VL - 29

SP - 14

EP - 18

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 4 SUPPL. 3

ER -